araag2/HINT huggingface dataset:
Clinical trial NCT02753400 (phase 2, status: completed)
Conditions: proliferative diabetic retinopathy
ICD codes: H35.23, H35.20, H35.21, H35.22, E10.3553, E11.3553, E13.3553
Drugs: emixustat hydrochloride
SMILES: NCC[C@@H](O)C1=CC(OCC2CCCCC2)=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Able and willing to provide written informed consent

          -  Documented diagnosis of type 1 or type 2 diabetes mellitus

          -  Meets specific ocular criteria for the study eye including but not limited to, the
             presence of PDR with or without diabetic macular edema in study eye for which
             treatment can be deferred for at least 4 weeks after Day 1 visit

          -  Media clarity, pupillary dilation, and subject cooperation sufficient to obtain
             adequate assessments

        Exclusion Criteria:

          -  Any condition that would preclude participation in the study (e.g., unstable medical
             status including blood pressure, cardiovascular disease or glycemic control)

          -  History of myocardial infarction or other acute cardiac event

          -  History of chronic renal failure requiring dialysis or kidney transplant

          -  Prior participation in any clinical study of emixustat

          -  Treatment with any investigational study drug within 30 days of screening

          -  Known allergy to fluorescein sodium for injection in angiography

          -  Treatment with specific prohibited medications or therapy beginning 4 weeks prior to
             screening and throughout the duration of the study

          -  History of systemic anti-VEGF or pro-VEGF treatment within 4 months prior to
             randomization

          -  Pre-specified laboratory abnormalities at screening

          -  Specific ocular characteristics in the study eye

          -  Male subjects who are not surgically sterile and are not willing to practice a
             medically accepted method of birth control with their female partner of childbearing
             potential from screening through 30 days following completion of the study

          -  Female subjects of childbearing potential who are not willing to practice a medically
             accepted method of birth control with their non-surgically sterile male sexual partner
             from screening through 30 days following completion of the study

          -  Female subjects who are pregnant or lactating
Clinical trial NCT02756013 (phase 2, status: terminated)
Conditions: gynecologic malignancies
ICD codes: Y76.0, Y76.1, Y76.2, Y76.3, Y76.8, Z01.411, Z01.419
Drugs: paclitaxel, carboplatin
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, N[C@@H](CCCNC(N)=N)C(O)=O
Reason stopped: 
    lack of accrual - terminated
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with a histologically confirmed or presumed diagnosis of gynecologic
             malignancy for whom chemotherapy with paclitaxel and carboplatin is planned.

          -  Body Surface area >2.0

          -  Patients must have adequate:

               -  Renal function: Creatinine <1.5 x Institutional upper limits of normal (ULN)

               -  Bone marrow function:

                    -  Absolute neutrophil count (ANC) ≥ 1,500/mcl. This ANC cannot have been
                       induced or supported by granulocyte colony stimulating factors.

                    -  Platelets ≥ 100,000/mcl.

               -  Hepatic function:

                    -  Bilirubin ≤ 1.5 x ULN.

                    -  Aspartate aminotransferase (AST) (SGOT) ≤ 2.5 x ULN.

                    -  Alkaline phosphatase ≤ to 2.5 x ULN.

               -  Neurologic function:

                    -  Neuropathy (sensory and motor) ≤ CTCAE Grade 1.

          -  Patients must have a Eastern Cooperative Oncology Group (ECOG) Performance Status of
             0, 1, or 2.

          -  Patients must be entered within 12 weeks of diagnosis.

          -  Subjects must have the ability to understand and the willingness to sign a written
             informed consent document.

        Exclusion Criteria:

          -  Patients who have received prior radiotherapy to any portion of the abdominal cavity
             or pelvis. Prior radiation for localized cancer of the breast, head and neck, or skin
             is permitted, provided that it was completed more than three years prior to
             registration, and the patient remains free of recurrent or metastatic disease.

          -  Patients who have received prior chemotherapy.

          -  Patients with acute hepatitis or active infection that requires parenteral
             antibiotics.

          -  Patients with clinically significant cardiovascular disease. This includes:

               -  Myocardial infarction or unstable angina < 6 months prior to registration.

               -  New York Heart Association (NYHA) Grade II or greater congestive heart failure

               -  Serious cardiac arrhythmia requiring medication. This does not include
                  asymptomatic, atrial fibrillation with controlled ventricular rate.

          -  Patients who are pregnant or nursing.

          -  Patients with medical history or conditions not otherwise previously specified which
             in the opinion of the investigator should exclude participation in this study.

          -  Patients with known allergy to cremophor or polysorbate 80.
Clinical trial NCT02757729 (phase 2, status: completed)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: pac-14028 cream 0.1%, pac-14028 cream 0.3%, pac-14028 cream 1.0%, pac-14028 cream vehicle
SMILES: CCCC1=C(\C=C\C(=O)N[C@H](C)C2=CC(F)=C(NS(C)(=O)=O)C(F)=C2)C=CC(=N1)C(F)(F)F, CCCC1=C(\C=C\C(=O)N[C@H](C)C2=CC(F)=C(NS(C)(=O)=O)C(F)=C2)C=CC(=N1)C(F)(F)F, CCCC1=C(\C=C\C(=O)N[C@H](C)C2=CC(F)=C(NS(C)(=O)=O)C(F)=C2)C=CC(=N1)C(F)(F)F, CCCC1=C(\C=C\C(=O)N[C@H](C)C2=CC(F)=C(NS(C)(=O)=O)C(F)=C2)C=CC(=N1)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients aged 19 - 70 years.

          -  Who was diagnosed with Atopic Dermatitis according to Haniffin and Rajka criteria.

          -  Whose affected BSA is over 5% and IGA score is 2 (mild) to 3 (moderate).

          -  Who voluntarily agreed to participate in the study and signed an informed consent
             form.

        Exclusion Criteria:

          -  Who has skin diseases other than atopic dermatitis or scar in the affected area which
             can affect the study, determined by the study investigators.

          -  Who has clinically significant medical history or diseases involving liver, kidney,
             neurological system, psychical disorder that can affect study results.

          -  Who has used systemic steroids, antibiotics, immunosuppressants, or received
             photochemical therapy within 28 days before study drug administration.

          -  Who has used topical steroids, immunosuppressants or antibiotics to treat atopic
             dermatitis within 14 days before study drug administration.

          -  Who has used or is expected to inevitably use prohibited concomitant medications
             during the study.

          -  Women who is pregnant /breast-feeding, or who has childbearing potential and does not
             use available contraceptives.

          -  Who has dosed other study medications within 30 days before screening.

          -  Who is determined ineligible for study participation by investigators for any other
             reasons.
Clinical trial NCT02775448 (phase 2, status: terminated)
Conditions: dyslipidemia, menopause, obesity
ICD codes: E28.310, E28.319, E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: carduus marianus 6ch, carduus marianus 12ch, carduus marianus 30ch, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    difficulties in recruiting process
  
Eligibility criteria:

        Inclusion Criteria:

          1. women 40-65 years in early or late transition to menopause or postmenopause according
             to STRAW classification

          2. hypertriglyceridemia [>150 <1000 mg/dL], and/or hypercholesterolemia [>200mg/dL]

          3. overweight or obesity [BMI >25 Kg/m2]

          4. fasting glucose <126mg/dL

          5. glycosylated hemoglobin <6.5%

          6. be willing and capable to follow study procedures.

        Exclusion Criteria:

          1. history of cardiovascular disease or coronary risk equivalents

          2. secondary hyperlipidemia caused by diabetes mellitus, renal, liver or thyroid diseases

          3. hypolipidemic agents, antidiabetic medication, hormone replacement therapy, tamoxifen,
             raloxifene, danazol, isotretinoin, acitretin, cyclosporin, azathioprine, protease
             inhibitors (amprenavir, indinavir, nelfinavir, ritonavir, saquinavir), antipsychotics
             (clozapine), seizure medication (carbamazepine, valproic acid, phenobarbital,
             phenytoin) either on-going or any time in the previous 2 months

          4. any other clinically significant illness that, in the opinion of the investigator,
             might put the patient at risk of harm during the study or might adversely affect the
             interpretation of the study data

          5. pregnancy or breastfeeding.
Clinical trial NCT02775916 (phase 2, status: completed)
Conditions: primary sjögren's syndrome
ICD codes: D68.61, D69.41, D81.4, E24.1, E26.01, E26.81, E34.0
Drugs: cdz173, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of primary Sjögren's syndrome (pSS)

          -  ESSDAI score ≥ 6 at screening visit

        Exclusion Criteria:

          -  Secondary Sjögren's syndrome

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT02776137 (phase 2, status: completed)
Conditions: head-and-neck cancer, squamous cell carcinoma
ICD codes: C44.520, C44.92, C44.02, C44.321, C44.521, C44.82, C44.42
Drugs: docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          1. Histologically confirmed squamous cell carcinoma of the head and neck.Site of tumor
             origin in the oral cavity, oropharynx, larynx, or hypopharynx (excluding nasopharynx,
             or sinuses)

          2. Gross total resection, with pathology demonstrating one or more of the following risk
             factors:

               1. Histologic extracapsular nodal extension

               2. Histologic involvement of ≥ 2 regional lymph nodes

               3. Invasive cancer seen on microscopic evaluation of the resection margin, with no
                  evidence of gross tumor residual

          3. No evidence of distant metastases

          4. No synchronous or concurrent head and neck primary tumors

          5. Karnofsky score over 60

          6. Adequate organ function including the following:

               1. Absolute neutrophil count (ANC) >= 1.5 * 10^9/l

               2. Platelets count >= 100 * 10^9/l

               3. Hemoglobin >= 10 g/dl

               4. AST and ALT <= 2.5 times institutional upper limit of normal (ULN)

               5. Total bilirubin <= 1.5 times institutional ULN

               6. Creatinine clearance >= 50 ml/min

               7. Serum creatine <= 1 times ULN

          7. Signed written informed consent

        Exclusion Criteria:

          1. Evidence of distant metastasis

          2. Prior chemotherapy or anti-cancer biologic therapy for any type of cancer, or prior
             radiotherapy to the head and neck region

          3. Other previous cancer, except for in situ cervical cancer and cutaneous basal cell
             carcinoma

          4. Pregnant or breast-feeding females, or females and males of childbearing potential not
             taking adequate contraceptive measures

          5. Presence of an uncontrolled concomitant illness including, but not limited to, ongoing
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,
             or cardiac arrhythmia
Clinical trial NCT02776163 (phase 2, status: unknown status)
Conditions: salivary gland tumors, head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: cisplatin, docetaxel
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          1. Pathologically proven diagnosis of a malignant salivary gland tumor of intermediate or
             high-grade

          2. Pathologic stage T3-4 or N1-3 or T1-2, N0 with a close (≤ 5mm) or microscopically
             positive surgical margin

          3. Surgical resection with curative intent within 8 weeks prior to registration, with no
             evidence of gross tumor residual

          4. No evidence of distant metastases

          5. No synchronous or concurrent head and neck primary tumors

          6. Karnofsky score over 60

          7. Adequate organ function including the following:

               1. Absolute neutrophil count (ANC) >= 1.5 * 10^9/l

               2. Platelets count >= 100 * 10^9/l

               3. Hemoglobin >= 10 g/dl

               4. AST and ALT <= 2.5 times institutional upper limit of normal (ULN)

               5. Total bilirubin <= 1.5 times institutional ULN

               6. Creatinine clearance >= 50 ml/min

               7. Serum creatine <= 1 times ULN

          8. Signed written informed consent

        Exclusion Criteria:

          1. Evidence of distant metastasis

          2. Prior chemotherapy or anti-cancer biologic therapy for any type of cancer, or prior
             radiotherapy to the head and neck region

          3. Other previous cancer, except for in situ cervical cancer and cutaneous basal cell
             carcinoma

          4. Pregnant or breast-feeding females, or females and males of childbearing potential not
             taking adequate contraceptive measures

          5. Presence of an uncontrolled concomitant illness including, but not limited to, ongoing
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,
             or cardiac arrhythmia
Clinical trial NCT02778399 (phase 2, status: completed)
Conditions: endometriosis
ICD codes: N80.8, N80.9, N80.0, N80.1, N80.5, N80.2, N80.3
Drugs: placebo, obe2109
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  The subject must have had her most recent surgical and - if available - histological,
             diagnosis of pelvic endometriosis up to 10 years before screening.

          -  The subject has moderate to severe endometriosis-associated pain during the screening
             period.

          -  The subject has regular menstrual cycles.

          -  The subject has a BMI ≥ 18 kg/m2 at the screening visit.

        Key Exclusion Criteria:

          -  The subject is pregnant or breast feeding or is planning a pregnancy within the
             duration of the treatment period of the study.

          -  The subject had an interventional surgery for endometriosis performed within a period
             of 60 days before screening.

          -  The subject did not respond to prior treatment with gonadotropin releasing hormone
             (GnRH) agonists or GnRH antagonists for endometriosis.

          -  The subject has a history of, or known osteoporosis or other metabolic bone disease.

          -  The subject has chronic pelvic pain that is not caused by endometriosis and requires
             chronic analgesic / therapy, or that would interfere with the assessment of
             endometriosis related pain.
Clinical trial NCT02780167 (phase 2, status: completed)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: pf-04965842, pf-04965842, pf-04965842, pf-04965842, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects between 18 75 years of age, inclusive, at time of informed
             consent.

          -  Must have the following atopic dermatitis criteria:

               1. Have a clinical diagnosis of chronic atopic dermatitis (also known as atopic
                  eczema) for at least 1 year prior to Day 1 and has confirmed atopic dermatitis
                  (Hanifin and Rajka criteria of AD refer to Appendix 2) at the Screening visit.

               2. Have inadequate response to treatment with topical medications given for at least
                  4 weeks, or for whom topical treatments are otherwise medically inadvisable (eg,
                  because of important side effects or safety risks) within 12 months of the first
                  dose of study drug.

               3. Moderate to severe AD (affected BSA >=10 %, IGA >=3, and EASI >=12 at the
                  screening and baseline visits).

        Exclusion Criteria:

          -  History of human immunodeficiency virus (HIV) or positive HIV serology at screening,

          -  Infected with hepatitis B or hepatitis C viruses.

          -  Have evidence of active or latent or inadequately treated infection with Mycobacterium
             tuberculosis (TB)

          -  Have received any of the following treatment regiments specified in the timeframes
             outlined below:

        Within 6 months of first dose of study drug: Any cell depleting agents Within 12 weeks of
        first dose of study drug: Any studies with JAK inhibitors; Other biologics Within 8 weeks
        of first dose of study drug: Participation in other studies involving investigational
        drug(s) Within 6 weeks of first dose of study drug: Have been vaccinated with live or
        attenuated live vaccine.

        Within 4 weeks of first dose of study drug: Use of oral immune suppressants; Phototherapy
        (NB UVB) or broad band phototherapy; Regular use (more than 2 visits per week) of a tanning
        booth/parlor.

        Within 1 week of first dose of study drug: Topical treatments that could affect atopic
        dermatitis; Herbal medications with unknown properties or known beneficial effects for AD.
Clinical trial NCT02781558 (phase 2, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: sof/vel, rbv
SMILES: [H][C@](N=C(O)OC)(C(C)C)C(=O)N1[C@@]([H])(C)CC[C@@]1([H])C1=NC2=C(N1)C1=CC3=C(C=C1C=C2)C1=C(CO3)C=C(C=C1)C1=CN=C(N1)[C@]1([H])C[C@]([H])(COC)CN1C(=O)[C@]([H])(N=C(O)OC)C1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  Individuals with chronic genotype 3 HCV infection and compensated cirrhosis

          -  Individuals with or without HIV-1 coinfection

        Key Exclusion Criteria:

          -  History of clinically significant illness or any other medical disorder that may
             interfere with individual's treatment assessment or compliance with the protocol

          -  Co-infection with active hepatitis B virus

          -  Laboratory results outside the acceptable ranges at screening

          -  Pregnant or nursing female

          -  Chronic liver disease not caused by HCV

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT02782858 (phase 2, status: completed)
Conditions: multiple sclerosis, relapsing-remitting
ICD codes: G35, G93.81, K74.1, Q85.1, G12.21, G12.23, M34.0
Drugs: gnbac1, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Main Inclusion Criteria:

          -  For male or female with reproductive potential, use of reliable means of
             contraception;

          -  RRMS according to the 2010 revised McDonald criteria;

          -  Disease activity characterised by at least one documented relapse within the last 12
             months and /or at least one Gd-enhancing T1 lesion at selection or evidenced within
             the last 3 months;

          -  EDSS score < 6.0.

        Main Exclusion Criteria:

          -  Patients suffering from Secondary Progressive MS and Primary Progressive MS at
             screening;

          -  Pregnant and nursing women.
Clinical trial NCT02784002 (phase 2, status: completed)
Conditions: clostridium difficile infection
ICD codes: A05.2, A04.71, A04.72, B96.7
Drugs: ridinilazole, fidaxomicin
SMILES: CC[C@H]1\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(CC)C(Cl)=C(O)C(Cl)=C3O)[C@H](O)[C@@H]2OC)\C(=O)OC(C\C=C(/C)\C=C(C)\[C@@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]1O)[C@@H](C)O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed Consent

          -  Clinical diagnosis of CDI plus laboratory diagnostic test

          -  No more than 30 hours antimicrobial treatment for current CDI episode

          -  Female subjects of childbearing potential must use adequate contraception

        Exclusion Criteria:

          -  Life-threatening or fulminant CDI

          -  Subjects with 2 or more episodes of CDI in the previous year

          -  Females who are pregnant or breastfeeding

          -  History of inflammatory bowel disease

          -  Co-administration of potent P-glycoprotein inhibitors

          -  Participation in other Clinical research studies within one month of screening

          -  Subjects that the Investigator feels are inappropriate for the study